Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gilead Sciences shares | $59.705

Own Gilead Sciences stock in just a few minutes.

Fact checked
Gilead Sciences logo

Gilead Sciences, Inc (GILD) is a leading drug manufacturers—general business based in the US. It opened the day at USD$60 after a previous close of USD$60.11. During the day the price has varied from a low of USD$59.365 to a high of USD$60.285. The latest price was USD$59.705 (25 minute delay). Gilead Sciences is listed on the NASDAQ and employs 11,800 staff. All prices are listed in US Dollars.

About our promoted products: Our 'promoted' products are presented as a result of a commercial advertising arrangement or to highlight a particular feature. Promoted products are not a recommendation, an indication a product is the best in its category, nor represent all products in the market. It is important to compare your options and find the right product for you. Some of our promoted products are CFD providers. CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment

How to buy shares in Gilead Sciences from New Zealand

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Gilead Sciences Find the stock by name or ticker symbol: GILD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Gilead Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$60.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Gilead Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Gilead Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

US share trading platforms

Data indicated here is updated regularly
Name Product Min. monthly fee Currency conversion fee Available markets
Stake
$0
1% ($2 min)
NASDAQ, NYSE, BATS, Chicago Stock Exchange, and more
Sign up through Finder and use referral code "FINDERNZ" for a free stock. Trade more than 3,800 US-listed stocks and ETFs through Stake with $0 fees on trades.
Hatch
$0
0.5%
NASDAQ, NYSE
Invest in more than 3,500 US companies and exchange-traded funds (ETFs). No minimum investment or monthly fees.
Sharesies
$0
0.4%
NASDAQ, NYSE, NZX, CBOE
loading

Compare up to 4 providers

Invest in a shares CFD

Important: By investing in a share CFD, you are speculating on the price movement of that share and do not have ownership of the underlying asset. CFDs are complicated financial products are are more suited to experienced trader. Learn more about CFD trading
Data indicated here is updated regularly
Name Product Minimum Opening Deposit Minimum Opening Deposit Commission Available Markets Platforms
Plus500 CFD
NZ 100
100
No commission
Global shares, indices, options, ETFs
Plus500 Web Trader
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment.Trade CFDs on shares, forex, indices, commodities and more.
IG Markets CFDs
AUD 0
0
0.08% with $7 minimum
Indices, Options, FX, Shares, Commodities, Cryptocurrency, ETPs
MetaTrader 4
ProReal Time
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment. Trade from over 15,000 markets with a leading service for CFD trading and forex.
BlackBull Markets CFD
USD 200
200
No commission
Indices, FX, Commodities, Precious Metals
MetaTrader 4, MetaTrader 5
CFDs are complex financial products and traders are at high-risk of losing all of or more than their initial investment. Trade CFDs on shares, forex, indices, commodities, precious metals and more.
loading

Compare up to 4 providers

Gilead Sciences share price

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

Information last updated 2020-11-23.
Open USD$60
High USD$60.285
Low USD$59.365
Close USD$59.705
Previous close USD$60.11
Change USD$-0.405
Change % -0.674%
Volume 5,320,064
Information last updated 2020-11-18.
52-week range USD$57.18 - USD$84.3279
50-day moving average USD$61.1511
200-day moving average USD$69.2193
Wall St. target price USD$74.04
PE ratio 61.8214
Dividend yield USD$2.72 (4.45%)
Earnings per share (TTM) USD$1.007

Gilead Sciences price performance over time

Historical closes compared with the last close of $59.705

1 week (2020-11-16) -2.27%
1 month (2020-10-23) -1.78%
3 months (2020-08-21) -10.22%
6 months (2020-05-22) -18.59%
1 year (2019-11-22) -8.51%
2 years (2018-11-23) -10.34%
3 years (2017-11-22) -18.01%
5 years (2015-11-23) -43.87%

Is Gilead Sciences under- or over-valued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, Gilead Sciences shares trade at around 62x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4399. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.3 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Shorting Gilead Sciences shares

There are currently 22.7 million Gilead Sciences shares held short by investors – that's known as Gilead Sciences's "short interest". This figure is 10.7% up from 20.5 million last month.

There are a few different ways that this level of interest in shorting Gilead Sciences shares can be evaluated.

Gilead Sciences's "short interest ratio" (SIR)

Gilead Sciences's "short interest ratio" (SIR) is the quantity of Gilead Sciences shares currently shorted divided by the average quantity of Gilead Sciences shares traded daily (recently around 10.4 million). Gilead Sciences's SIR currently stands at 2.18. In other words for every 100,000 Gilead Sciences shares traded daily on the market, roughly 2180 shares are currently held short.

However Gilead Sciences's short interest can also be evaluated against the total number of Gilead Sciences shares, or, against the total number of tradable Gilead Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gilead Sciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gilead Sciences shares in existence, roughly 20 shares are currently held short) or 0.0181% of the tradable shares (for every 100,000 tradable Gilead Sciences shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gilead Sciences.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use, Disclaimer & Privacy Policy.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site